Molecular characterization of basal-like and non-basal-like triple-negative breast cancer

Oncologist

Volumn 18, Issue 2, 2013, Pages 123-133

  Prat, Aleix ^a   Adamo, Barbara ^a   Cheang, MAGGIE C U ^b   Anders, Carey K ^b   Carey, Lisa A ^b   Perou, Charles M ^b,c  

^a VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Basal like; Breast cancer; Gene expression; Subtype; Triple negative

Indexed keywords

ALPHA6 INTEGRIN; ANDROGEN RECEPTOR; APOLIPOPROTEIN D; AURORA B KINASE; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLIN B2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 4; KERATIN; MUCIN 1; PROGESTERONE RECEPTOR; PROTEIN P53; PROTEIN TYROSINE KINASE; UVOMORULIN;

ADULT; ARTICLE; BASAL LIKE BREAST CANCER; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA MICROARRAY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER;

FEMALE; GENE EXPRESSION PROFILING; HUMANS; RECEPTOR, ERBB-2; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84874376997     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0397     Document Type: Article

References (59)

1. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-752.
2. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011;5:5-23.
3. Prat A, Ellis MJ, Perou CM. Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol 2012;9:48-57.
4. Sorlie T, Perou C, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-10874.
5. Nielsen TO, Parker JS, Leung S et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010;16:5222-5232.
6. Martn M, Rodrguez-Lescure Á, Ruiz A, et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst 2008; 100:805-814.
7. Bramwell VHC, Pritchard KI, Tu D, et al. A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada-Clinical Trials Group Trial, MA.12). Ann of Oncol. 2010;21:283-290.
8. Levine MN, Pritchard KI, Bramwell VHC, et al. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 2005;23:5166-5170.
9. Cheang M, Martin M, Nielsen T et al. Quantitative hormone receptors, triple-negative breast cancer (TNBC), and molecular subtypes: A collaborative effort of the BIG-NCI NABCG. Proc Am Soc Clin Oncol 2012;a1008.
10. Prat A, Parker J, Karginova O et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010;12:R68.
11. Lehmann BD, Bauer JA, Chen X et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2012;121:2750-2767.
12. Bos PD, Zhang XHF, Nadal C et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009;459:1005-1009.
13. Harrell J, Prat A, Parker J et al. Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res Treat 2012;132:523-535.
14. Wang Y, Klijn JG, Zhang Y et al. Gene-expression profiles to predict distant metastasis of lymphnode-negative primary breast cancer. Lancet 2005; 365:671-679.
15. Hatzis C, Pusztai L, Valero V et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 2011;305:1873-1881.
16. Popovici V, Chen W, Gallas B et al. Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res 12:R5.
17. Tabchy A, Valero V, Vidaurre T et al. Evaluation of a 30-Gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res 2010;16:5351-5361.
18. Iwamoto T, Bianchini G, Booser D et al. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst 2011;103:264-272.
19. Hess KR, Anderson K, Symmans WF et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006;24:4236-4244.
20. Dedeurwaerder S, Desmedt C, Calonne E et al. DNA methylation profiling reveals a predominant immune component in breast cancers. EMBO Molecular Medicine 2011;3:726-741.
21. International Genomics Consortium. expO offers free access to clinically annotated tumor data. Available at https://expo.intgen.org/geo/. Accessed January 18, 2013.
22. Minn AJ, Gupta GP, Siegel PM et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-524.
23. Li Y, Zou L, Li Q et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 2010;16:214-218.
24. Parker JS, Mullins M, Cheang MCU et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-1167.
25. Network TCGA. Comprehensive molecular portraits of human breast tumors. Nature 2012; 490:61-70.
26. Ding L, Ellis MJ, Li S et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010;464:999-1005.
27. Eisen MB, Spellman PT, Brown PO et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-14868.
28. Dennis G, Sherman BT, Hosack DA et al. DAVID: Database for annotation, visualization, and Integrated discovery. Genome Biol 2003;4:R60.
29. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98: 5116-5121.
30. Anders CK, Fan C, Parker JS et al. Breast carcinomas arising at a young age: Unique biology or a surrogate for aggressive intrinsic subtypes? J Clin Oncol 2011;29:e18-e20.
31. Fedele CG, Ooms LM, Ho M et al. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci U S A 2010;107:22231-22236.
32. Gewinner C, Wang ZC, Richardson A et al. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 2009;16:115-125.
33. Niemeier LA, Dabbs DJ, Beriwal S et al. Androgen receptor in breast cancer: Expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol 2009;23:205-212.
34. Doane AS, Danso M, Lal P et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006;25: 3994-4008.
35. Farmer P, Bonnefoi H, Becette V et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005;24:4660-4671.
36. Gucalp A, Tolaney SM, Isakoff SJ et al. TBCRC 011: Targeting the androgen receptor (AR) for the treatment of AR /ER /PR metastatic breast cancer (MBC). ASCO Meeting Abstracts 2011;29: TPS122.
37. Hammond MEH, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784-2795.
38. Prat A, Parker J, Fan C et al. PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer. Breast Cancer Res Treat 2012;135:301-306.
39. Herschkowitz JI, Simin K, Weigman VJ et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007;8:R76.
40. Katz E, Dubois-Marshall S, Sims AH et al. An in vitro model that recapitulates the epithelial to mesenchymal transition (EMT) in human breast cancer. PLoS ONE 2011;6:e17083.
41. Walia V, Yu Y, Cao D et al. Loss of breast epithelial marker hCLCA2 promotes epithelial-to-mesenchymal transition and indicates higher risk of metastasis. Oncogene 2012;31:2237-2246.
42. Raviraj V, Zhang H, Chien H-Y et al. Dormant but migratory tumour cells in desmoplastic stroma of invasive ductal carcinomas. Clin Exp Metastasis 2012;29:273-292.
43. Hollern DP, Yuwanita I, Andrechek ER. A mouse model with T58A mutations in Myc reduces the dependence on KRas mutations and has similarities to claudin-low human breast cancer. Oncogene 2012 [Epub ahead of print].
44. Xu K, Usary J, Kousis Philaretos C et al. Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer. Cancer Cell 21:626-641.
45. Gerhard R, Ricardo S, Albergaria A et al. Immunohistochemical features of claudin-low intrinsic subtype in metaplastic breast carcinomas. Breast 2012;21:354-360.
46. Beltran A, Rivenbark A, Richardson B et al. Generation of tumor-initiating cells by exogenous delivery of OCT4 transcription factor. Breast Cancer Res 2012;13:R94.
47. Keller PJ, Arendt LM, Skibinski A et al. Defining the cellular precursors to human breast cancer. Proc Natl Acad Sci 2012;109:2772-2777.
48. Neve R, Chin K, Fridlyand J et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-527.
49. Kao J, Salari K, Bocanegra M et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS ONE 2009;4:e6146.
50. Hollestelle A, Nagel J, Smid M et al. Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treat 2010;121:53-64.
51. Rody A, Holtrich U, Pusztai L et al. T-cell metagene predicts a favourable prognosis in estrogen receptor negative and HER2 positive breast cancers. Breast Cancer Res 2009;11:R15.
52. Fan C, Prat A, Parker J et al. Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med Genomics 2011;4:3.
53. Place A, Jin Huh S, Polyak K. The microenvironment in breast cancer progression: Biology and implications for treatment. Breast Cancer Res 2011; 13:227.
54. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008;358:1409-1411.
55. Cameron D, Brown J, Dent R et al. Primary results of BEATRICE, a randomized phase III trial evaluating adjuvant bevacizumab-containing therapy in triple-negative breast cancer. Paper presented at: Cancer Therapy and Research Center-American Association for Cancer Research San Antonio Breast Cancer Symposium; December 4-8, 2012; San Antonio, TX.
56. Silver DP, Richardson AL, Eklund AC et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010;28:1145-1153.
57. Mahmoud SMA, Paish EC, Powe DG et al. Tumor-infiltrating CD8 lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011;29: 1949-1955.
58. Liu S, Lachapelle J, Leung S et al. CD8 lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res 2012;14:R48.
59. Brahmer JR, Tykodi SS, Chow LQM et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-2465.